4-氰基-3-氟苯甲酸甲酯 | 268734-34-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-3-氟苯甲酸甲酯
• 中文别名: 甲基4-氰基-3-氟苯甲酸；3-氟-4-氰基苯甲酸甲酯
• 英文名称: methyl 4-cyano-3-fluorobenzoate
• CAS: 268734-34-5
• 化学式: C₉H₆FNO₂
• mdl: MFCD09264509
• 分子量: 179.151
• InChiKey: AHJLHWRWDRCIKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温和干燥环境

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: methyl 4-cyano-3-fluorobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: methyl 4-cyano-3-fluorobenzoate
CAS number: 268734-34-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6FNO2
Molecular weight: 179.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

4-氰基-3-氟苯甲酸甲酯的应用前景非常广阔。近年来，它已成为制备工艺研究的热点。这种化合物可以由多种化合物为起始物料制得。

应用

4-氰基-3-氟苯甲酸甲酯易溶于有机溶剂，是一种重要的合成医药和农药中间体，也是合成液晶材料的主要原料。它在农药、染料等领域有着广泛的应用。

反应信息

• 作为反应物：
  描述：

  4-氰基-3-氟苯甲酸甲酯 在 sodium tetrahydroborate 、 四磷十氧化物 、 sodium hydride 、 potassium bromide 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 73.0h， 生成 tert-butyl {(tert-butoxy)-N-[(4-cyano-3-fluorophenyl)methyl]carbonylamino}formate
  参考文献：
  名称：

  底物-模拟弗林蛋白酶抑制剂的优化

  摘要：

  前蛋白转化酶弗林蛋白酶是药物设计的潜在目标，尤其是对于抑制弗林蛋白酶依赖性病毒复制的抑制。到目前为止，鉴定出的所有有效的合成弗林蛋白酶抑制剂都是多元化合物。我们以前开发的抑制剂4-（胍基甲基）苯基乙酰基-Arg-Tle-Arg-4-ami基苄基酰胺（MI-1148）被发现具有最高的效价。小鼠的初步研究表明，该四元化合物的治疗范围狭窄，而某些三元类似物的毒性则大大降低。这表明毒性至少在某种程度上取决于该抑制剂的整体多元特性。因此，在第一种方法中，将MI-1148的C末端联苯胺替换为碱性较低的P1残基。尽管效力降低，但仍有少数化合物在低纳摩尔范围内抑制弗林蛋白酶，但在细胞中的功效微不足道。在第二种方法中，将P2精氨酸替换为赖氨酸。与MI-1148相比，这种弗林蛋白酶抑制剂的效力略有降低，但在细胞培养中对西尼罗河和登革热病毒表现出相似的抗病毒活性，在小鼠中的毒性也有所降低。这些结果为开发有效且耐

  DOI：

  10.1002/cmdc.201700596
• 作为产物：
  描述：

  2-氟-4-溴苯腈 在 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 4-氰基-3-氟苯甲酸甲酯
  参考文献：
  名称：

  Farnesyltransferase inhibitors

  摘要：

  具有以下化学式的取代咪唑和噻唑对抑制法尼基转移酶具有用处。还公开了抑制法尼基转移酶的组合物和在患者中抑制法尼基转移酶的方法。

  公开号：

  US20030087940A1

文献信息

• Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2)
  作者：Jayakanth Kankanala、Christophe Marchand、Monica Abdelmalak、Hideki Aihara、Yves Pommier、Zhengqiang Wang

  DOI：10.1021/acs.jmedchem.5b01973

  日期：2016.3.24

  isoquinoline-1,3-dione as a viable chemotype for selectively inhibiting TDP2. The initial hit compound 43 was identified by screening our in-house collection of synthetic compounds. Further structure–activity relationship (SAR) studies identified numerous analogues inhibiting TDP2 in low micromolar range without appreciable inhibition against the homologous TDP1 at the highest testing concentration

  酪氨酰DNA磷酸二酯酶II（TDP2）是最近发现的一种酶，可特异性修复拓扑异构酶II（Top2）毒物引起的DNA损伤并引起对这些药物的耐药性。预期抑制TDP2可增强临床上重要的靶向Top2的抗癌药的功效。但是，作为治疗靶标的TDP2仍然知之甚少。我们在此报告了异喹啉-1,3-二酮作为选择性抑制TDP2的可行化学型的发现。最初的打击化合物43通过筛选我们内部的合成化合物来鉴定。进一步的结构活性关系（SAR）研究发现，在最高测试浓度（111μM）下，许多类似物在低微摩尔范围内抑制TDP2，而对同源TDP1没有明显的抑制作用。最佳化合物64抑制重组TDP2，IC 50为1.9μM 。这种化学型的发现可以为理解TDP2作为药物靶标提供一个平台。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080119457A1

  公开（公告）日：2008-05-22

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 31 , and R 41 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  公开了公式I的化合物和药用盐，其中A、Q1、Q2、Q3、R31和R41如本文所定义。公式I的化合物在治疗与细胞增殖相关的疾病和/或病况方面具有用途，如癌症、炎症、关节炎、血管生成等。还公开了包括本发明化合物的药物组合物以及使用这些化合物治疗上述病况的方法。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：CTXT PTY LTD

  公开号：WO2019243491A1

  公开（公告）日：2019-12-26

  A compound of formula (I), or a pharmaceutical salt thereof.

  式(I)的化合物，或其药用盐。
• Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
  申请人：——

  公开号：US20030186989A1

  公开（公告）日：2003-10-02

  Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0): 1 wherein R 5 and R 6 are taken together to form a moiety of partial Formulas (1.1.1) through (1.1.5): 2 or a pharmaceutically acceptable salt thereof.

  在治疗由嗜酸性粒细胞的激活和脱颗粒调节的疾病，特别是哮喘、慢性支气管炎和慢性阻塞性肺病中作为PDE4抑制剂有用的化合物，其化学式为（1.0.0）： 其中R5和R6一起取代形成部分化学式（1.1.1）至（1.1.5）的基团， 或其药用可接受的盐。
• [EN] INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS<br/>[FR] MODULATEURS A BASE DE DERIVES INDOLIQUES DES RECEPTEURS NUCLEAIRES DES HORMONES STEROIDES
  申请人：LILLY CO ELI

  公开号：WO2004067529A1

  公开（公告）日：2004-08-12

  The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.

  本发明提供了一种I式化合物或其药学上可接受的盐，包括I式化合物的有效量与适当载体、稀释剂或赋形剂组合而成的药物组合物，以及治疗生理紊乱的方法，特别是充血性心脏病，包括向患者施用I式化合物的有效量。